Things must be going well for Bristol Myers Squibb’s legacy Celgene-Evotec neurodegeneration partnership. The New York Big Pharma has decided to add another eight years to their agreement, boosting the overall potential deal value to $4 billion.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,